Castle

Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer

Retrieved on: 
Thursday, April 4, 2024
Oncology, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Sentinel lymph node, SCC, Congress, Castle, Risk, Patient, Neoplasm, Research, NCCN, AJCC, National Comprehensive Cancer Network, Risk assessment, Lymph node, Carcinoma, Melanoma, Trial of the century, Recurrence, Metastasis, SLN, Medical imaging

Summary: The DecisionDx-Melanoma test has been validated to predict individual risk of SLNB positivity and five-year risk of recurrence and metastasis for patients with CM.

Key Points: 
  • Summary: The DecisionDx-Melanoma test has been validated to predict individual risk of SLNB positivity and five-year risk of recurrence and metastasis for patients with CM.
  • This study explored the cost-savings impact of using the DecisionDx-Melanoma test to guide risk-aligned clinical decision-making versus using the current melanoma staging standard, a patient’s AJCC stage.
  • Summary: The DecisionDx-SCC test uses a patient’s tumor biology to independently predict risk of regional or distant metastasis in patients with high-risk SCC.
  • These data demonstrate that DecisionDx-SCC improves the accuracy of risk assessment based solely on clinicopathological risk factors, leading to more appropriate risk-aligned management plans for patients with high-risk SCC.

Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
Tuesday, April 2, 2024
Research, Medical Devices, Genetics, Health Technology, Other Health, Biotechnology, Health, Science, Oncology, Other Science, Webcast, Castle, Conference

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to present a company overview at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 12:45 p.m. Eastern time.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to present a company overview at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 12:45 p.m. Eastern time.
  • A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at https://ir.castlebiosciences.com/events-presentations/default.aspx .
  • A replay of the webcast will be available following the conclusion of the live broadcast.

Williams Homes, Inc. Announces Internal Promotions of Seven Key Executive Leadership Posts

Retrieved on: 
Thursday, March 14, 2024
Construction & Property, Residential Building & Real Estate, David Seidner, Castle, Marketing, Home, Faina, Pardee Homes, Management

“These gentlemen are genuine attributes to our executive management team,” said Lance Williams, Williams Homes’ chairman and CEO.

Key Points: 
  • “These gentlemen are genuine attributes to our executive management team,” said Lance Williams, Williams Homes’ chairman and CEO.
  • “As the company continues to grow, we are only as good as the vision, work ethic and leadership of those around us.
  • Milano has been promoted to division president, Southern California after joining Williams Homes in 2021 and serving as vice president of land acquisitions.
  • Von Quilich will serve as interim division president, Texas while maintaining his existing role as division president, Northern California.

Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum

Retrieved on: 
Tuesday, March 12, 2024
Medical Supplies, Biotechnology, Health, Pharmaceutical, Oncology, Mental Health, Health Technology, Other Science, Medical Devices, Genetics, Science, Webcast, Castle, Medtech

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to present a company overview at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024, at 11:15 a.m. Eastern time.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to present a company overview at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024, at 11:15 a.m. Eastern time.
  • A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at https://ir.castlebiosciences.com/events-presentations/default.aspx .
  • A replay of the webcast will be available following the conclusion of the live broadcast.

IMG Saxony-Anhalt presents its new tourism offers at ITB Berlin 2024 - a plus in overnight stays by foreign guests

Retrieved on: 
Wednesday, March 20, 2024
Citadel, Saale-Unstrut, Castle, Magdeburg Cathedral, Harz, ITB, IMG, Reformation, Bauhaus Museum, Travel, Brocken Railway, News, Iron, German National Tourist Board, UNESCO, Marketing, City, Investment, Tourism, Naumburg Cathedral, Iron Curtain, Culture, Bauhaus Dessau, GNTB, All Saints' Church, Wittenberg

According to the State Statistical Office, overnight tourism in Saxony-Anhalt has now almost returned to the level of the pre-pandemic year 2019.

Key Points: 
  • According to the State Statistical Office, overnight tourism in Saxony-Anhalt has now almost returned to the level of the pre-pandemic year 2019.
  • This corresponds to an increase of seven percent in guest arrivals and six percent in overnight stays compared to the previous year.
  • Also, eleven percent more international guests came to Saxony-Anhalt with over a quarter of a million arrivals, which clearly exceeds the pre-Corona level.
  • This good news and the new offers "Hello, Saxony-Anhalt" were presented at the joint booth of the German National Tourist Board (GNTB) at the ITB 2024.

IMG Saxony-Anhalt presents its new tourism offers at ITB Berlin 2024 - a plus in overnight stays by foreign guests

Retrieved on: 
Monday, March 18, 2024
Citadel, Saale-Unstrut, Castle, Magdeburg Cathedral, Harz, ITB, IMG, Reformation, Bauhaus Museum, Travel, Brocken Railway, News, Iron, German National Tourist Board, UNESCO, Marketing, City, Investment, Tourism, Naumburg Cathedral, Iron Curtain, Culture, Bauhaus Dessau, GNTB, All Saints' Church, Wittenberg

According to the State Statistical Office, overnight tourism in Saxony-Anhalt has now almost returned to the level of the pre-pandemic year 2019.

Key Points: 
  • According to the State Statistical Office, overnight tourism in Saxony-Anhalt has now almost returned to the level of the pre-pandemic year 2019.
  • This corresponds to an increase of seven percent in guest arrivals and six percent in overnight stays compared to the previous year.
  • Also, eleven percent more international guests came to Saxony-Anhalt with over a quarter of a million arrivals, which clearly exceeds the pre-Corona level.
  • This good news and the new offers "Hello, Saxony-Anhalt" were presented at the joint booth of the German National Tourist Board (GNTB) at the ITB 2024.

IMG Saxony-Anhalt presents its new tourism offers at ITB Berlin 2024 - a plus in overnight stays by foreign guests

Retrieved on: 
Monday, March 18, 2024
Citadel, Saale-Unstrut, Castle, Magdeburg Cathedral, Harz, ITB, IMG, Reformation, Bauhaus Museum, Travel, Brocken Railway, News, Iron, German National Tourist Board, UNESCO, Marketing, City, Investment, Tourism, Naumburg Cathedral, Iron Curtain, Culture, Bauhaus Dessau, GNTB, All Saints' Church, Wittenberg

According to the State Statistical Office, overnight tourism in Saxony-Anhalt has now almost returned to the level of the pre-pandemic year 2019.

Key Points: 
  • According to the State Statistical Office, overnight tourism in Saxony-Anhalt has now almost returned to the level of the pre-pandemic year 2019.
  • This corresponds to an increase of seven percent in guest arrivals and six percent in overnight stays compared to the previous year.
  • Also, eleven percent more international guests came to Saxony-Anhalt with over a quarter of a million arrivals, which clearly exceeds the pre-Corona level.
  • This good news and the new offers "Hello, Saxony-Anhalt" were presented at the joint booth of the German National Tourist Board (GNTB) at the ITB 2024.

Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting

Retrieved on: 
Friday, March 8, 2024
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, JAAD, Risk, Annual general meeting, AAD, Skin, Abstract, Patient, Castle, GEP, Dermatology, American Academy, Pharmaceutical industry

In the study, use of the DecisionDx-Melanoma test was associated with improved melanoma-specific survival relative to untested patients.

Key Points: 
  • In the study, use of the DecisionDx-Melanoma test was associated with improved melanoma-specific survival relative to untested patients.
  • The study data demonstrate that clinicians are utilizing the DecisionDx-SCC test appropriately for patients with high-risk cutaneous squamous cell carcinoma (SCC).
  • These data support incorporating the test’s results into clinical practice to improve the accuracy of risk predictions to guide more personalized treatment plans for patients.
  • Approximately 80% of clinically tested lesions with a malignant MyPath result have sufficient biopsy tumor content for DecisionDx-Melanoma testing.

Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results

Retrieved on: 
Wednesday, February 28, 2024
Mental Health, Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Science, Oncology, Well, Neoplasm, Psoriasis, DecisionDx-UM, Investment, News, Growth, Table, Uveal melanoma, Epidemiology, SCC, Webcast, Diagnosis, Mortality, Woman, Melanoma, Cohort (statistics), Recurrence, BWH, Overalls, Radiation, Metastasis, Mycosis fungoides, GAAP, Journal, Net, Depreciation, PSO, Major depressive disorder, Randomized controlled trial, Atopic dermatitis, Adjustment, Practitioner, ART, Castle, National Comprehensive Cancer Network, Survival, MDD, Workflow, Acquisition, MF, Risk, Medicare, NCCN, Patient, Pharmaceutical industry

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2023.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2023.
  • DecisionDx-SCC test reports delivered in the quarter were 3,530, compared to 1,845 in the fourth quarter of 2022, an increase of 91%.
  • DecisionDx-UM test reports delivered in the quarter were 405, compared to 432 in the fourth quarter of 2022, a decrease of 6%.
  • Castle Biosciences will hold a conference call on Wednesday, Feb. 28, 2024, at 4:30 p.m. Eastern time to discuss its fourth quarter and full-year 2023 results and provide a corporate update.

Leading Attorney Jason Adams Joins Cox, Castle & Nicholson as Partner

Retrieved on: 
Thursday, February 22, 2024
Commercial Building & Real Estate, Construction & Property, Legal, Professional Services, Multimedia, Risk management, CRIS, Risk, Partner, Castle, Senior counsel, American Arbitration Association, Insurance

Cox, Castle & Nicholson LLP , a leading full-service law firm specializing in real estate in the United States, announced today that seasoned attorney Jason Adams has joined the firm as a Partner.

Key Points: 
  • Cox, Castle & Nicholson LLP , a leading full-service law firm specializing in real estate in the United States, announced today that seasoned attorney Jason Adams has joined the firm as a Partner.
  • Adams joins Cox Castle’s litigation team, which has decades of experience partnering with its clients to find the shortest route from conflict to resolution.
  • “I am thrilled to join Cox Castle as a Partner and excited to work with some of the brightest attorneys in the nation,” said Adams.
  • Adams is a fellow with the Construction Law Society of America, and serves as a mediator and arbitrator with the American Arbitration Association.